Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent.

          2. Patients must have a histologically or cytologically confirmed recurrent or metastatic
             pancreatic adenocarcinoma.

          3. No prior systemic therapy for metastatic or recurrent disease.

               -  Prior adjuvant gemcitabine, if completed more than 12 months prior to date of
                  enrollment, is acceptable.

               -  Radiosensitizing chemotherapy, if completed at least 4 weeks from date of
                  enrollment, is acceptable.

          4. Measurable disease is required per RECIST1.1 criteria.

          5. Age 18-70 years at the time of enrollment.

        7. ECOG performance status 0 or 1. 8. Have resolution of toxic effect(s) or intervention
        complication to Grade 1 or less (except alopecia) from any prior chemotherapy, major
        surgery, or radiation therapy of >30 Gy.

        9. Adequate hematologic, hepatic, and renal function. All screening labs should be
        performed within 14 days of enrollment date.

          -  Hemoglobin ≥ 10 g/dL

          -  ANC ≥ 1,500/µL

          -  Platelets ≥ 100,000/µL

          -  Total bilirubin < 1.5 x institutional ULN

          -  AST (SGOT) & ALT(SGPT)≤ 2.5 x institutional ULN in patients without known liver
             metastasis; ≤ 5 x institutional ULN in patients with known liver metastasis

          -  Serum creatinine ≤ 1.5 times ULN, and calculated creatinine clearance ≥ 60 mL/min
             using the Cockcroft-Gault equation)

          -  INR or PT International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 times the
             ULN

          -  Albumin ≥ 3.0 g/dL

             10. Female patients of childbearing potential must have a negative pregnancy test
             (either urine or serum pregnancy test) within 72 hours prior to the first dose of
             study treatment. If the urine pregnancy test is positive or cannot be confirmed as
             negative, a serum pregnancy test will be required. A female of child-bearing potential
             is any woman (regardless of sexual orientation, having undergone a tubal ligation, or
             remaining celibate by choice) who meets the following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months).

                  11. Women of child-bearing potential and men must agree to use adequate
                  contraception (hormonal or barrier method of birth control; abstinence) prior to
                  study entry, for the duration of study participation, and for 120 days following
                  completion of therapy. Should a woman become pregnant or suspect she is pregnant
                  while participating in this study, she should inform her treating physician, or
                  study team member, immediately.

        Exclusion Criteria:

          1. Is currently participating and receiving study therapy in a first line setting for
             metastatic or reccurent pancreatic adenocarcinoma.

          2. Participated in a study of an investigational agent or used an investigational device
             within 4 weeks of the first dose of study treatment.

          3. Patients with known untreated brain metastases. Patients without known or suspected
             brain metastases do not require radiologic imaging prior to enrollment.

          4. Has a known additional malignancy that is progressing or requires active treatment.
             Note: Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of
             the skin that has undergone potentially curative therapy or in situ cervical cancer.

          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, significant pulmonary disease (shortness of breath at rest or mild
             exertion), or uncontrolled infection or psychiatric illness/social situations that
             would limit compliance with study requirements.

          6. History of the following cardiac conditions:

               1. Congestive cardiac failure of >Grade II severity according to the NYHA (defined
                  as symptomatic at less than ordinary levels of activity);

               2. Ischemic cardiac event including myocardial infarction within 3 months prior to
                  date of enrollment

               3. Uncontrolled cardiac disease, including unstable angina pectoris, uncontrolled
                  hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg),
                  cardiac arrhythmia, or need to change medication due to lack of disease control
                  within 6 weeks prior to date of enrollment;

               4. History or presence of sustained bradycardia (≤55 BPM), left bundle branch block,
                  cardiac pacemaker or ventricular arrhythmia. Note: Patients with a
                  supraventricular arrhythmia requiring medical treatment, but with a normal
                  ventricular rate are eligible;

               5. Known family history or personal history of long QTc syndrome or previous
                  drug-induced QTc prolongation of at least Grade 3 (QTc >500 ms).

          7. Abnormal left ventricular ejection fraction (LVEF) on ECHO or MUGA less than <45%.

          8. Current treatment with any agent known to cause Torsades de Pointes which cannot be
             discontinued at least five half-lives or two weeks prior to the first dose of study
             treatment.

          9. Screening 12-lead ECG, in triplicate, with a measurable QTc interval according to
             Fridericia's correction >450 ms.

         10. Known active infection with human immunodeficiency virus (HIV), hepatitis B or C
             viruses (screening not required, follow institutional practise):

               1. Patients who have a history of hepatitis B infection are eligible provided they
                  are hepatitis B surface antigen negative.

               2. Patients who have a history of hepatitis C infection are eligible provided they
                  have no evidence of hepatitis C ribonucleic acid using a quantitative polymerase
                  chain reaction assay at least 6 months after completing treatment for hepatitis C
                  infection.

         11. Active, clinically significant serious infection requiring treatment with antibiotics,
             anti-virals or anti-fungals.

         12. Treatment with any medication which is predominantly metabolized by CYP3A4 and has a
             narrow therapeutic index

         13. Major surgery within 4 weeks prior to date of enrollment; excluding skin biopsies and
             procedures for insertion of central venous access devices.

         14. Inability to tolerate oral medication

         15. Existing gastrointestinal disease affecting drug absorption such as celiac disease or
             Crohn's disease, or previous bowel resection which is considered to be clinically
             significant or could interfere with absorption.

         16. Known lactose intolerance

         17. Is pregnant or breastfeeding

         18. Any significant medical condition lab abnormality, or psychiatric illness, in the
             opinion of the investigator, that might interfere with the patient's participation in
             the study or in the evaluation of the study results.

         19. Unwillingness or inability to comply with study procedures.